Efficacy of modified recombinant type II collagen in modulating autoimmune arthritis

Arthritis and Rheumatism

Volumn 50, Issue 9, 2004, Pages 3004-3011

  Myers, L K ^a   Tang, B ^a   Brand, D D ^a,b   Rosloniec, E F ^a,b   Stuart, J M ^a,b   Kang, A H ^a,b  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINE; ASPARTIC ACID; COLLAGEN TYPE 2; COLLAGEN TYPE 2 [256-276]; CYTOKINE; GLUTAMIC ACID; INTERLEUKIN 4; PHENYLALANINE; RECOMBINANT COLLAGEN TYPE 2; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTHRITIS; ARTICLE; AUTOIMMUNE DISEASE; BACULOVIRUS; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SYNTHESIS; GENETIC RECOMBINATION; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOPHARMACOLOGY; IMMUNOTHERAPY; MOUSE; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN MODIFICATION; TH2 CELL; TRANSGENIC MOUSE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ARTHRITIS, EXPERIMENTAL; CATTLE; COLLAGEN TYPE II; CYTOKINES; DOWN-REGULATION; HLA-DR1 ANTIGEN; HUMANS; MICE; MICE, TRANSGENIC; MODELS, ANIMAL; MUTATION; TH2 CELLS;

EID: 4444292398     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.20491     Document Type: Article

References (44)

1. Courtenay JS, Dallman MJ, Dayan AD, Martin A, Mosedale B. Immunization against heterologous type II collagen induces arthritis in mice. Nature 1980;283:666-8.
2. Trentham DE, Townes AS, Kang AH. Autoimmunity to type II collagen: an experimental model of arthritis. J Exp Med 1977;146:857-68.
3. Trentham DE, Dynesius RA, David JR. Passive transfer by cells of type II collagen-induced arthritis in rats. J Clin Invest 1978;62:359-66.
4. Wooley PH, Luthra HS, Stuart JM, David CS. Type II collagen-induced arthritis in mice. I. Major histocompatibility complex (I region) linkage and antibody correlates. J Exp Med 1981;154:688-700.
5. Wooley PH, Dillon AM, Luthra HS, Stuart JM, David CS. Genetic control of type II collagen-induced arthritis in mice: factors influencing disease susceptibility and evidence for multiple MHC-associated gene control. Transplant Proc 1983;15:180-6.
6. Wooley PH, Luthra HS, Krco CJ, Stuart JM, David CS. Type II collagen-induced arthritis in mice. II. Passive transfer and suppression by intravenous injection of anti-type II collagen antibody or free native type II collagen. Arthritis Rheum 1984;27:1010-7.
7. Fugger L, Rothbard JB, Sonderstrup-McDevitt G. Specificity of an HLA-DRB1 *0401-restricted T cell response to type II collagen. Eur J Immunol 1996;26:928-33.
8. Kawamura S, Miyahara H, Esaki Y, Myers LK, Rosloviec EF, Stuart JM, et al. Restricted TCR Va repertoire in the T cell response to a tolerogenic determinant of type II collagen. J Immunol 1997;158:6013-8.
9. Cremer MA, Rosloniec EF, Kang AH. The cartilage collagens: a review of their structure, organization, and role in the pathogenesis of experimental arthritis in animals and in human rheumatic disease. J Mol Med 1998;76:275-88.
10. Myers LK, Tang B, Rosloniec EF, Stuart JM, Chiang TM, Kang AH. Characterization of a peptide analog of a determinant of type II collagen that suppresses collagen-induced arthritis. J Immunol 1998;161:3589-95.
11. Michaelsson E, Malmstrom V, Reis S, Engstrom A, Burkhardt H, Holmdahl R. T cell recognition of carbohydrates on type II collagen. J Exp Med 1994;180:745-9.
12. Axford JS. 4th Jenner International Glycoimmunology Meeting. Immunol Today 1997;18:511-3.
13. Corthay A, Backlund J, Broddefalk J, Michaelsson E, Goldschmidt TJ, Kihlberg J, et al. Epitope glycosylation plays a critical role for T cell recognition of type II collagen in collagen-induced arthritis. Eur J Immunol 1998;28:2580-90.
14. Stuart JM, Cremer MA, Dixit SN, Kang AH, Townes AS. Collagen-induced arthritis in rats: comparison of vitreous and cartilage-derived collagens. Arthritis Rheum 1979;22:347-52.
15. Nokelainen M, Helaakoski T, Myllyharju J, Notbohm H, Pihlajaniemi T, Fietzek PP, et al. Expression and characterization of recombinant human type II collagens with low and high contents of hydroxylysine and its glycosylated forms. Matrix Biol 1998;16:329-38.
16. Myers LK, Brand DD, Ye XJ, Cremer MA, Rosloniec EF, Bodo M, et al. Characterization of recombinant type II collagen: arthritogenicity and tolerogenicity in DBA/1 mice. Immunology 1998;95:631-9.
17. Rosloniec EF, Brand DD, Myers LK, Whittington KB, Gumanovskaya M, Zaller DM, et al. An HLA-DR1 transgene confers susceptibility to collagen-induced arthritis elicited with human type II collagen. J Exp Med 1997;185:1113-22.
18. Kuhn R, Rajewsky K, Muller W. Generation and analysis of interleukin-4 deficient mice. Science 1991;254:707-10.
19. Rosloniec EF, Kang AH, Myers LK, Cremer MA. Collagen-induced arthritis. In: Coico R, Shevach E, editors. Current protocols in immunology. New York: Wiley & Sons; 1997. p. 1-24.
20. Backlund J, Carlsen S, Hoger T, Holm B, Fugger L, Kihlberg J, et al. Predominant selection of T cells specific for the glycosylated collagen type II epitope (263-270) in humanized transgenic mice and in rheumatoid arthritis. Proc Natl Acad Sci U S A 2002;99:9960-5.
21. Evavold BD, Allen PM. Separation of IL-4 production from Th cell proliferation by an altered T cell receptor ligand. Science 1991;252:1308-10.
22. Alexander J, Snoke K, Ruppert J, Sidney J, Wall M, Southwood S, et al. Functional consequences of engagement of the T cell receptor by low affinity ligands. J Immunol 1993;150:1-7.
23. Pfeiffer C, Stein J, Southwood S, Ketelaar H, Sette A, Bottomly K. Altered peptide ligands can control CD4 T lymphocyte differentiation in vivo. J Exp Med 1995;181:1569-74.
24. Tao X, Constant S, Jorritsma P, Bottomly K. Strength of TCR signal determines the costimulatory requirements for Th1 and Th2 CD4+ T cell differentiation. J Immunol 1997;159:5956-63.
25. Tao X, Grant C, Constant S, Bottomly K. Induction of IL-4-producing CD4+ T cells by antigenic peptides altered for TCR binding. J Immunol 1997;158:4237-44.
26. Kersh GJ, Allen PM. Structural basis for T cell recognition of altered peptide ligands: a single T cell receptor can productively recognize a large continuum of related ligands. J Exp Med 1996;184:1259-68.
27. Evavold BD, Sloan-Lancaster J, Hsu BL, Allen PM. Separation of T helper 1 clone cytolysis from proliferation and lymphokine production using analog peptides. J Immunol 1993;150:3131-40.
28. Evavold BD, Sloan-Lancaster J, Allen PM. Tickling the TCR: selective T-cell functions stimulated by altered peptide ligands. Immunol Today 1993;14:602-9.
29. Bielekova B, Goodwin B, Richert N, Cortest I, Kondo T, Afshar G, et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med 2000;6:1167-75.
30. Bielekova B, Martin R. Antigen-specific immunomodulation via altered peptide ligands. J Mol Med 2001;79:552-65.
31. Nicholson LB, Waldner H, Carrizosa AM, Sette A, Collins M, Kuchroo VK. Heteroclitic proliferative responses and changes in cytokine profile induced by altered peptides: implications for autoimmunity. Proc Natl Acad Sci U S A 1998;95:264-9.
32. Pearson CI, Smilek DE, Danska JS, McDevitt HO. Induction of a heterogeneous TCR repertoire in (PL/JXSJL/J)F1 mice by myelin basic protein peptide Ac1-11 and its analog Ac1-11[4A]. Mol Immunol 1997;34:781-92.
33. Paas-Rozner M, Sela M, Mozes E. The nature of the active suppression of responses associated with experimental autoimmune myasthenia gravis by a dual altered peptide ligand administered by different routes. Proc Natl Acad Sci U S A 2001;98:12642-7.
34. Mossman TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989;7:145-73.
35. Tomkinson A, Duez C, Cieslewicz G, Pratt C, Joetham A, Shanafelt MD, et al. A murine IL-4 receptor antagonist that inhibits IL-4- and IL-13-induced responses prevents antigen-induced airway eosinophilia and airway hyperresponsiveness. J Immunol 2001;166:5792-800.
36. Joosten LA, Lubberts E, Helsen MM, Saxne T, Coenen-de Roo CJ, Heinegard D, et al. Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis. Arthritis Res 1999;1:81-91.
37. Kim SH, Kim S, Evans CH, Ghivizzani SC, Oligino T, Robbins PD. Effective treatment of established murine collagen-induced arthritis by systemic administration of dendritic cells genetically modified to express IL-4. J Immunol 2001;166:3499-505.
38. Watanabe S, Imagawa T, Boivin GP, Gao G, Wilson JM, Hirsch R. Adeno-associated virus mediates long-term gene transfer and delivery of chondroprotective IL-4 to murine synovium. Mol Ther 2000;2:147-52.
39. Stastny P, Ball E, Kahn M, Olsen N, Pincus T, Gao X. HLA-DR4 and other genetic markers in rheumatoid arthritis. Br J Rheumatol 1988;27:132-8.
40. Nepom GT, Byers P, Seyfried C, Healey LA, Eilske KR, Stage D, et al. HLA genes associated with rheumatoid arthritis: identification of susceptibility alleles using specific oligonucleotide probes. Arthritis Rheum 1989;32:15-21.
41. Fernandez-Vina M, Fink CW, Stastny P. HLA associations in juvenile arthritis. Clin Exp Rheumatol 1994;12:205-14.
42. Berg L, Ronnelid J, Sanjeevi CB, Lampa J, Klareskog L. T cell reactivity to collagen type II in rheumatoid arthritis is associated with HLA-DR4 and HLA-DQ8. Arthritis Rheum 1998;41 Suppl 9:S164.
43. Cho ML, Lee SK, Lee SS, Joo YS, Kim WU, Min JK, et al. Enhanced T cell proliferative response to native bovine type II collagen and its immunodominant epitope (CII 255-274) in patients with rheumatoid arthritis. Arthritis Rheum 1998;41 Suppl 9:S164.
44. Kappos L, Comi G, Panitch H, Oger J, Antel J, Conlon P, et al, for the Altered Peptide Ligand in Relapsing MS Study Group. Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. Nat Med 2000;6:1176-82.